Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare but devastating dermatological emergencies that require immediate intervention. A 10-year study by Pagliaro T et al. recently evaluated SJS TEN management outcomes at a major tertiary center. This retrospective analysis provides crucial insights into how specialized care influences survival rates in these complex patients. Understanding these factors is vital for Indian clinicians dealing with drug-induced cutaneous reactions.

The research, conducted at the Royal Brisbane and Women's Hospital, involved 52 adult cases. Notably, the study reported a mortality rate of only 9.6%, which is remarkably low compared to historical data. Researchers analyzed several variables, including disease severity (SCORTEN), time taken to reach definitive care, and the use of systemic immunosuppressants. Interestingly, they found that while SCORTEN remains a reliable predictor of mortality, neither the specific systemic treatment nor the delay in admission significantly impacted survival. Consequently, the quality of multidisciplinary care in ICU and Burns units appears to be the most decisive factor for survival.

Improving SJS TEN Management Outcomes Through Multidisciplinary Care

Specialized multidisciplinary teams are essential for managing the extensive skin loss and systemic complications associated with SJS/TEN. Therefore, early referral to a tertiary center with a dedicated Burns or ICU unit remains a cornerstone of management strategies. Furthermore, the findings suggest that the choice of immunomodulatory therapy—whether corticosteroids, cyclosporine, or IVIG—may be less critical than meticulous supportive care. This aligns with recent observations that infection control and fluid balance are the primary drivers of recovery. Additionally, clinicians must continue to monitor patients closely using the SCORTEN tool to identify those at high risk. As a result, hospitals can optimize resource allocation for the most severe cases.

In India, antibiotics and anticonvulsants are the most common triggers for these conditions. Practitioners should emphasize early recognition and immediate cessation of the suspected culprit drug. Moreover, despite the debate surrounding systemic therapies, supportive measures such as electrolyte management and mucosal care must never be neglected. For example, maintaining an ambient temperature and using non-adherent dressings are vital for wound healing. By adopting a comprehensive, team-based approach, medical facilities can significantly improve the clinical trajectory and long-term prognosis of affected individuals.

Frequently Asked Questions

What is the role of SCORTEN in managing SJS/TEN?

SCORTEN is a validated prognostic tool that assesses seven clinical and laboratory parameters to estimate the risk of mortality. It helps clinicians prioritize intensive care for high-risk patients during the first few days of admission.

Does early administration of systemic steroids improve survival?

The impact of systemic steroids remains controversial. While some studies suggest benefits, recent cohort analyses indicate that specialized supportive care in a multidisciplinary setting may be more significant in determining overall mortality outcomes.

What are the most common causes of death in SJS/TEN patients?

Sepsis and multi-organ failure are the leading causes of mortality. Therefore, maintaining a sterile environment, managing fluids, and preventing secondary infections are critical components of patient care.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Pagliaro T et al. A 10-Year Retrospective Cohort Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at the Royal Brisbane and Women's Hospital. Australas J Dermatol. 2026 Feb 24. doi: 10.1111/ajd.70076. PMID: 41736175.

2. Gupta LK et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603-625.

3. Kumar R et al. Clinico-Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients. Indian J Dermatol. 2024;69(1):40-47.